drugset / Trial / NCT00246298
A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients
Phase 2
Terminated
31 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Ortho Biotech Products, L.P. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if PROCRIT® (a glycoprotein that stimulates red blood cell production) initiated at once every 2 weeks dosing is as effective as PROCRIT® initiated at once a week dosing, in increasing hemoglobin levels in anemic HIV-infected subjects.
Timeline
- Start
- 2005-10
- Primary completion
- —
- Completion
- 2006-09
Outcome
Outcome not reported
Stopped (Business): “OBI business decision not to complete any additional research in HIV.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | — |